Vancouver, British Columbia — November 7, 2025 — Leads & Copy — BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) has announced the pricing of its underwritten public offering of 2,485,000 shares of common stock at a public offering price of $7.00 per share. The company expects gross proceeds of approximately $17.4 million before deducting underwriting discounts and other offering expenses.
BioHarvest has granted the underwriters a 30-day option to purchase up to 372,750 additional shares of its common stock at the public offering price, less the underwriting discount. Subject to customary conditions, the offering is expected to close on or about November 10, 2025.
Craig-Hallum is serving as the sole managing underwriter for the offering.
BioHarvest intends to use the net proceeds for research and development, manufacturing, marketing, advancing its CDMO business unit, debt reduction or refinancing, capital expenditures, and general corporate purposes, including funding working capital.
The offering is being made under a shelf registration statement on Form F-3 (File No. 333-289908), including a base prospectus, initially filed with the SEC on August 28, 2025, and declared effective on September 8, 2025. The final prospectus supplement will be available on the SEC’s website.
Copies of the final prospectus supplement and accompanying base prospectus may be obtained from Craig-Hallum Capital Group LLC.
BioHarvest leverages its patented Botanical Synthesis technology platform to grow plant-based compounds without growing the underlying plant. The company develops science-based and clinically proven therapeutic solutions within two business verticals: a contract development and production organization (CDMO) and proprietary nutraceutical health and wellness products.
Dave Ryan, VP Investor Relations
+1 (604) 622-1186
info@bioharvest.com
Lucas A. Zimmerman
Managing Director
MZ Group – MZ North America
+1 (949) 259-4987
BHST@mzgroup.us
Source: BioHarvest Sciences Inc.
